[go: up one dir, main page]

ME02674B - Terapeutske upotrebe 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina - Google Patents

Terapeutske upotrebe 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina

Info

Publication number
ME02674B
ME02674B MEP-2017-94A MEP9417A ME02674B ME 02674 B ME02674 B ME 02674B ME P9417 A MEP9417 A ME P9417A ME 02674 B ME02674 B ME 02674B
Authority
ME
Montenegro
Prior art keywords
phenylsulfanyl
piperazine
dimethyl
phenyl
drug
Prior art date
Application number
MEP-2017-94A
Other languages
German (de)
English (en)
French (fr)
Inventor
Marianne Dragheim
Ioana Florea
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02674(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of ME02674B publication Critical patent/ME02674B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (4)

1. 1-[2-{2,4-dimetil-fenilsulfanil)fenil]piperazin i njegove farmaceutski prihvatljive soli za upotrebu u tretiranju depresije ili anksioznosti kod pacijenta koji je prethodno primao lek za tretiranje pomenute bolesti, koji lek je ukinut zbog neželjenih efekata povezanih sa težinom.
2.1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazin i njegove farmaceutski prihvatljive soli prema zahtevu koji je so bromovodonika.
3.Upotreba 1-[2-{2,4-dimetil-fenilsulfanil)fenil]piperazina i njegovih farmaceutski prihvatljivih soli u pripremanju leka za tretiranje depresije ili anksioznosti kod pacijenta koji je prethodno primao lek za tretiranje pomenute bolesti, koji le k je ukinut zbog neželjenih efekata povezanih sa težinom.
4.Upotreba prema zahtevu 3, u kojoj pomenuta farmaceutski prihvatljiva so je so bromovodonika.
MEP-2017-94A 2010-08-23 2011-08-22 Terapeutske upotrebe 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina ME02674B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37588510P 2010-08-23 2010-08-23
DKPA201000739 2010-08-23
PCT/DK2011/050317 WO2012025123A1 (en) 2010-08-23 2011-08-22 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
EP11749331.2A EP2608789B2 (en) 2010-08-23 2011-08-22 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Publications (1)

Publication Number Publication Date
ME02674B true ME02674B (me) 2017-06-20

Family

ID=44532506

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-94A ME02674B (me) 2010-08-23 2011-08-22 Terapeutske upotrebe 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina

Country Status (32)

Country Link
US (5) US20130184291A1 (me)
EP (1) EP2608789B2 (me)
JP (1) JP5902169B2 (me)
KR (1) KR101816953B1 (me)
CN (1) CN103068389A (me)
AP (1) AP3583A (me)
AR (1) AR082501A1 (me)
AU (1) AU2011295465B8 (me)
BR (2) BR122020025600A2 (me)
CA (1) CA2807062C (me)
CL (1) CL2013000492A1 (me)
CO (1) CO6680652A2 (me)
CY (1) CY1118886T1 (me)
DK (1) DK2608789T4 (me)
ES (1) ES2625142T5 (me)
FI (1) FI2608789T4 (me)
HR (1) HRP20170608T4 (me)
HU (1) HUE034155T2 (me)
IL (1) IL224371A (me)
LT (1) LT2608789T (me)
ME (1) ME02674B (me)
MX (1) MX349724B (me)
PL (1) PL2608789T5 (me)
PT (1) PT2608789T (me)
RS (1) RS55851B2 (me)
RU (1) RU2564666C2 (me)
SG (1) SG187649A1 (me)
SI (1) SI2608789T2 (me)
SM (1) SMT201700239T1 (me)
TW (1) TW201212918A (me)
WO (1) WO2012025123A1 (me)
ZA (1) ZA201301385B (me)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9822086B2 (en) 2014-01-31 2017-11-21 Egis Gyogyszergyar Zrt. Process for the preparation of vortioxetine salts
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN109310691A (zh) 2016-07-01 2019-02-05 H.隆德贝克有限公司 用于快速开始抗抑郁作用的给药方案
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
DE69210959T2 (de) * 1991-11-18 1996-09-26 Lilly Industries Ltd Benzo(b)thiophen-2-carboxamide zur Behandlung von Krankheiten des Zentralnervensystems
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
EP1322854A4 (en) 2000-10-02 2004-08-04 Rohr Inc APPARATUS, METHOD AND SYSTEM FOR REDUCING THE NOISE OF A GAS TURBINE
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
MY150647A (en) 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity

Also Published As

Publication number Publication date
CA2807062C (en) 2018-07-31
MX2013001570A (es) 2013-03-21
EP2608789B1 (en) 2017-04-12
US20220370439A1 (en) 2022-11-24
BR122020025600A2 (pt) 2021-01-05
AR082501A1 (es) 2012-12-12
HRP20170608T4 (hr) 2024-12-06
US20130184291A1 (en) 2013-07-18
SI2608789T2 (sl) 2025-05-30
SMT201700239T1 (it) 2017-07-18
AP3583A (en) 2016-02-09
TW201212918A (en) 2012-04-01
IL224371A (en) 2016-07-31
US20190000836A1 (en) 2019-01-03
ES2625142T5 (en) 2025-02-10
AU2011295465A1 (en) 2013-02-07
WO2012025123A1 (en) 2012-03-01
US20240293397A1 (en) 2024-09-05
ZA201301385B (en) 2014-04-30
RU2564666C2 (ru) 2015-10-10
SG187649A1 (en) 2013-03-28
JP2013536206A (ja) 2013-09-19
HRP20170608T1 (hr) 2017-07-28
DK2608789T4 (da) 2024-11-04
MX349724B (es) 2017-08-10
LT2608789T (lt) 2017-05-25
CY1118886T1 (el) 2018-01-10
AU2011295465B8 (en) 2014-07-10
DK2608789T3 (en) 2017-05-15
RU2013112890A (ru) 2014-09-27
KR101816953B1 (ko) 2018-01-09
JP5902169B2 (ja) 2016-04-13
CA2807062A1 (en) 2012-03-01
EP2608789B2 (en) 2024-08-21
PL2608789T3 (pl) 2017-09-29
PL2608789T5 (pl) 2025-11-12
AU2011295465B2 (en) 2014-06-19
PT2608789T (pt) 2017-05-26
BR112013002194A2 (pt) 2016-05-31
CN103068389A (zh) 2013-04-24
CO6680652A2 (es) 2013-05-31
SI2608789T1 (sl) 2017-06-30
HUE034155T2 (en) 2018-01-29
KR20130097162A (ko) 2013-09-02
ES2625142T3 (es) 2017-07-18
US20210085674A1 (en) 2021-03-25
AP2013006768A0 (en) 2012-03-31
FI2608789T4 (fi) 2024-11-01
RS55851B1 (sr) 2017-08-31
CL2013000492A1 (es) 2013-06-07
EP2608789A1 (en) 2013-07-03
RS55851B2 (sr) 2024-11-29

Similar Documents

Publication Publication Date Title
ME02674B (me) Terapeutske upotrebe 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina
HRP20120144T1 (en) Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
IL229199A (en) N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs
UA112317C2 (uk) Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
HRP20180709T1 (hr) Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona
EA201490419A1 (ru) Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
MY160036A (en) Pyrazole compounds as crth2 antagonists
NZ709648A (en) Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-methyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl)benzamide and its mono hydrochloride salt
MX387125B (es) Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma.
DK2164492T3 (da) Trans-4-{2-[4-(2,3-dichlorphenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoylcyclohexylamin til behandling af skizofreni
IL230487B (en) 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them
NZ628408A (en) Ingenol derivatives in reactivation of latent hiv virus
HRP20200662T1 (hr) Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak
PH12015500012B1 (en) Benzodioxole derivative and preparation method and use thereof
MX378947B (es) Composición farmacéutica estable para administración oral.
EA201071209A1 (ru) Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови
RU2019104946A (ru) Применение производного хромона в качестве антагониста дофаминового рецептора d3 для лечения расстройства аутистического спектра
TN2014000177A1 (en) Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
WO2014081709A3 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
IL220698A (en) Annotation (s) –n– (4– (4– acetylpiperazine – 1 – ram) benzyl) - n– (1– (4 – benzylpiperazine – 1 – ram) –1 – oxo-3-phenyl-propane-2-ram ) Acrylamide, containing and using pharmaceutical preparations for the preparation of medicines
MX2015018040A (es) Agentes terapeuticos para uso en la profilaxis y/o tratamiento de trastornos de movimiento hipercinetico.
MX378175B (es) Novedosos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.